Targeting Immune Cell Wiring in Ulcerative Colitis.

[1]  F. Hoentjen,et al.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.

[2]  T. Winkler,et al.  IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. , 2019, The Journal of clinical investigation.

[3]  B. Sands,et al.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.

[4]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[5]  M. Neurath,et al.  Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. , 2019, Immunity.

[6]  M. Neurath.  IL-23 in inflammatory bowel diseases and colon cancer. , 2019, Cytokine & growth factor reviews.

[7]  M. Neurath,et al.  Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation , 2019, Nature Immunology.

[8]  R. Grützmann,et al.  Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease , 2018, Gut.

[9]  D. Gavhed,et al.  Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD , 2015, Gut.

[10]  M. Oukka,et al.  IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism , 2013, Mucosal Immunology.

[11]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[12]  A. Sher,et al.  IL-23 plays a key role in Helicobacter hepaticus–induced T cell–dependent colitis , 2006, The Journal of experimental medicine.